跳到主要导航 跳到搜索 跳到主要内容

TAD regimen with melphalan to treat 18 cases of multiple myeloma

  • Li Mei Chen
  • , Chao Min Li
  • , Huai Yu Wang
  • , Jian Hong Guan
  • , Xiao Li Ma
  • Xi'an Jiaotong University

科研成果: 期刊稿件 › 文章 › 同行评审

摘要

Objective: To observe the clinical results of combination therapy for multiple myeloma by arsenic trioxide, melphalan, vitamin C and dexamethasone. Methods: 18 cases with multiple myeloma, 12 males and 6 females were given the treatment including arsenic trioxide, melphalan, vitamin C and dexamethasone combination therapy; the dosage of arsenic trioxide 10 mg, d1-5, d8-12; vitamin C 1.0 g, d1-5, d8-12; dexamethasone 20 mg, d1-4, d8-11; melphalan 2 mg, tid, d1-12. Complete response(CR), partial response(PR), minimal response(MR), no change(NC) were observed. Results: The CR were 16.7 %(3/18), PR were 77.7 %(14/18), MR were 5.6 %(1/18). Conclusion: Combinational arsenic trioxide, melphalan, vitamin C and dexamethasone is an effective therapy with less side effects, which can be considered for treating the initial or relapsed or refractory MM.

源语言英语
页(从-至)351-352+355
期刊Journal of Leukemia and Lymphoma
卷17
期5
出版状态已出版 - 25 10月 2008

联合国可持续发展目标

此成果有助于实现下列可持续发展目标:

  1. 可持续发展目标 3 - 良好健康与福祉
    可持续发展目标 3 良好健康与福祉

学术指纹

探究 'TAD regimen with melphalan to treat 18 cases of multiple myeloma' 的科研主题。它们共同构成独一无二的学术指纹。

引用此